prikaz prve stranice dokumenta C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis
  Download
PDF 1004.25 KB
Scientific paper - Original scientific paper
C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis
Leukemia & Lymphoma, 61 (2020), 12; 2969-2974. https://doi.org/10.1080/10428194.2020.1789627
Lucijanić, Marko; Galušić, Davor; Krečak, Ivan; Sedinić, Martina; Sorić, Ena; Holik, Hrvoje; Periša, Vlatka; Morić Perić, Martina; Zekanović, Ivan; Štoos-Veić, Tajana; Kušec, Rajko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Lucijanić, M., Galušić, D., Krečak, I., Sedinić, M., Sorić, E., Holik, H. ... Kušec, R. (2020). C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis. Leukemia & Lymphoma, 61. (12), 2969-2974. doi: 10.1080/10428194.2020.1789627

Lucijanić, Marko, et al. "C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis." Leukemia & Lymphoma, vol. 61, no. 12, 2020, pp. 2969-2974. https://doi.org/10.1080/10428194.2020.1789627

Lucijanić, Marko, Davor Galušić, Ivan Krečak, Martina Sedinić, Ena Sorić, Hrvoje Holik, Vlatka Periša, et al. "C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis." Leukemia & Lymphoma 61, no. 12 (2020): 2969-2974. https://doi.org/10.1080/10428194.2020.1789627

Lucijanić, M., et al. (2020) 'C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis', Leukemia & Lymphoma, 61(12), pp. 2969-2974. doi: 10.1080/10428194.2020.1789627

Lucijanić M, Galušić D, Krečak I, Sedinić M, Sorić E, Holik H, and sur.. C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis. Leukemia & Lymphoma [Internet]. 2020 December [cited 2025 January 02];61(12):2969-2974. doi: 10.1080/10428194.2020.1789627

M. Lucijanić, et al., "C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis", Leukemia & Lymphoma, vol. 61, no. 12, pp. 2969-2974, December 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:774065. [Accessed: 02 January 2025]

Metadata
Title (english)C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis
AuthorMarko Lucijanić
AuthorDavor Galušić
AuthorIvan Krečak
AuthorMartina Sedinić
AuthorEna Sorić
AuthorHrvoje Holik
AuthorVlatka Periša
AuthorMartina Morić Perić
AuthorIvan Zekanović
AuthorTajana Štoos-Veić
AuthorRajko Kušec
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
We retrospectively investigated C reactive protein to albumin ratio (CAR) in a cohort of 142 patients with myelofibrosis [101 primary (PMF); 41 secondary (SMF)] and compared it to hematological and clinical parameters. Among other associations, higher CAR was significantly associated with higher grade of bone marrow fibrosis, lower frequency of Calreticulin (CALR) mutations, presence of constitutional symptoms, massive splenomegaly, transfusion dependency, blast phase disease, lower hemoglobin, lower platelets, higher ferritin and higher lactate dehydrogenase (LDH) (p < .05 for all analyses). Higher CAR was able to predict inferior survival in PMF independently of DIPSS [hazard ratio (HR)=2.17; p = .015 for high CAR and HR = 2.05; p < .001 for DIPSS] and in SMF independently of Mysec-PM (HR = 6.48; p = .022 for high CAR and HR = 2.63; p = .013 for Mysec-PM) demonstrating its good prognostic potential. CAR seems to be an independent and prognostically relevant parameter, both in PMF and SMF, and might aid in timely recognition of most vulnerable patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleLeukemia & Lymphoma
Numberingvol. 61, no. 12, pp. 2969-2974
p-ISSN1042-8194
e-ISSN1029-2403
DOIhttps://doi.org/10.1080/10428194.2020.1789627
URN:NBNurn:nbn:hr:105:774065
Publication2020-12
Document URLhttps://www.tandfonline.com/doi/full/10.1080/10428194.2020.1789627
Type of resourceText
Access conditionsOpen access
Embargo expiration date: 2022-01-01
Terms of useLicence In copyright icon
Created on2021-05-18 12:23:59